Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Gampenrieder · SciRah

Researcher profile · Semantic Scholar

S. Gampenrieder

Share profile

S. Gampenrieder — researcher profile on SciRah

h-index: 19
Works: 130
Citations: 1,562

Most-cited papers

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
G. Rinnerthaler, S. Gampenrieder, R. Greil
2019International Journal of Molecular Sciences184 citations Open access
Semantic Scholar
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
S. Gampenrieder, G. Rinnerthaler, C. Tinchon, A. Petzer +13 more
2021Breast Cancer Research120 citations Open access
Semantic Scholar
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
M. Gnant, F. Fitzal, G. Rinnerthaler, G. Steger +25 more
2021New England Journal of Medicine113 citations Open access
Semantic Scholar
Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer
F. Huemer, G. Rinnerthaler, T. Westphal, H. Hackl +4 more
2018OncoTarget87 citations Open access
Semantic Scholar
Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)
S. Gampenrieder, A. Peer, C. Weismann, M. Meissnitzer +13 more
2019Breast Cancer Research74 citations Open access
Semantic Scholar
Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
Qing Zhou, S. Gampenrieder, S. Frantal, G. Rinnerthaler +19 more
2021Clinical Cancer Research62 citations Open access
Semantic Scholar
Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade
F. Huemer, D. Lang, T. Westphal, S. Gampenrieder +6 more
2019Journal of Clinical Medicine57 citations Open access
Semantic Scholar
DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer
S. Gampenrieder, G. Rinnerthaler, H. Hackl, W. Pulverer +7 more
2018Theranostics35 citations Open access
Semantic Scholar
Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer.
M. Gnant, S. Frantal, G. Pfeiler, G. Steger +23 more
2022NEJM Evidence34 citations
Semantic Scholar
Cure in metastatic breast cancer
T. Westphal, S. Gampenrieder, G. Rinnerthaler, R. Greil
2018memo - Magazine of European Medical Oncology32 citations Open access
Semantic Scholar
Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial
T. Westphal, G. Rinnerthaler, S. Gampenrieder, J. Niebauer +10 more
2018Cancer Medicine30 citations Open access
Semantic Scholar
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes
V. Domenyuk, Z. Gatalica, R. Santhanam, Xixi Wei +25 more
2018Nature Communications27 citations Open access
Semantic Scholar
Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression
E. Klocker, S. Hasenleithner, R. Bartsch, S. Gampenrieder +11 more
2024Molecular Oncology20 citations Open access
Semantic Scholar
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group
S. Gampenrieder, V. Dezentje, M. Lambertini, A. de Nonneville +27 more
2022ESMO Open19 citations Open access
Semantic Scholar
ASCO 2018 highlights: metastatic breast cancer
G. Rinnerthaler, S. Gampenrieder, R. Greil
2018memo - Magazine of European Medical Oncology18 citations Open access
Semantic Scholar
Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study.
D. Niedersuess-Beke, Karl Mayrhofer, Johanna Krauter, Susanne Schnabel +25 more
2024Clinical Genitourinary Cancer16 citations Open access
Semantic Scholar
Pre-treatment 68 Ga-PSMA-11 PET/CT Prognostic Value in Predicting Response to 177Lu-PSMA-I&T Therapy and Patient Survival
Roya Eisazadeh, S. A. Mirshahvalad, Gregor Schwieghofer-Zwink, L. Hehenwarter +5 more
2024Molecular Imaging and Biology16 citations Open access
Semantic Scholar
Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options
S. Gampenrieder, V. Castagnaviz, G. Rinnerthaler, R. Greil
2020Cancer Management and Research15 citations Open access
Semantic Scholar
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)
G. Rinnerthaler, S. Gampenrieder, A. Petzer, S. Burgstaller +12 more
2018BMC Cancer12 citations Open access
Semantic Scholar
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial
G. Rinnerthaler, D. Egle, R. Bartsch, C. Schmitt +26 more
2025Nature Cancer11 citations Open access
Semantic Scholar
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.
A. Beltran-Bless, M. Clemons, C. Fesl, Richard Greil +19 more
2022European Journal of Cancer9 citations
Semantic Scholar
Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial
G. Rinnerthaler, S. Gampenrieder, H. Hackl, M. Steiner +9 more
2020Journal of Clinical Medicine9 citations Open access
Semantic Scholar
Comparison of high tone therapy and transcutaneous electrical nerve stimulation therapy in chemotherapy-induced polyneuropathy
D. Schaffler-Schaden, R. Sassmann, T. Johansson, S. Gampenrieder +9 more
2020Medicine9 citations Open access
Semantic Scholar
Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis
D. Niedersuess-Beke, Karl Mayrhofer, Johanna Krauter, Johannes Franke +27 more
2025International Journal of Cancer7 citations Open access
Semantic Scholar
“I was seen by a radiologist, but unfortunately I can’t remember the name and I still have questions. What should I do?” Radiologists should give thoughts to improve service professionalism and patient esteem
A. Gutzeit, A. Fischmann, R. Forstner, Romana Goette +17 more
2020Cancer Imaging7 citations Open access
Semantic Scholar
New Perspectives in the Management of Triple-Negative Breast Cancer
R. Bartsch, Z. Bagó-Horváth, D. Egle, S. Gampenrieder +9 more
2025Breast Care6 citations Open access
Semantic Scholar
Transcatheter aortic valve implantation in a patient with suspected hereditary von Willebrand disease and severe gastrointestinal bleeding – a case report
M. Mirna, M. Lichtenauer, T. Theurl, Mathias Ausserwinkler +6 more
2019Scottish Medical Journal6 citations
Semantic Scholar
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)
G. Rinnerthaler, S. Gampenrieder, A. Petzer, M. Hubálek +9 more
2021Therapeutic Advances in Medical Oncology5 citations Open access
Semantic Scholar
Nonmetastatic pancreatic cancer
S. Bachmayer, G. Fastner, A. Vaszi, W. Iglseder +9 more
2018Strahlentherapie und Onkologie (Print)5 citations Open access
Semantic Scholar
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
G. Rinnerthaler, S. Gampenrieder, R. Greil
2018memo - Magazine of European Medical Oncology5 citations Open access
Semantic Scholar
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
K. Wimmer, D. Hlauschek, M. Balić, G. Pfeiler +14 more
2024Breast Cancer Research and Treatment4 citations Open access
Semantic Scholar
Electrotherapy as treatment for chemotherapy-induced peripheral neuropathy — a randomized controlled trial
R. Sassmann, S. Gampenrieder, Florian Rieder, T. Johansson +8 more
2024Frontiers in Neurology4 citations Open access
Semantic Scholar
177P Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT)
S. Gampenrieder, V. Dezentje, M. Lambertini, A. de Nonneville +16 more
2022Annals of Oncology4 citations Open access
Semantic Scholar
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone
T. Magnes, S. Wagner, T. Melchardt, L. Weiss +10 more
2021Wiener Klinische Wochenschrift4 citations Open access
Semantic Scholar
283P Treatment landscape of HER2-positive metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry
S. Gampenrieder, G. Rinnerthaler, C. Tinchon, A. Petzer +13 more
2021Annals of Oncology4 citations Open access
Semantic Scholar
Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients
K. Schlick, Florian Hohla, F. Hamacher, H. Hackl +9 more
2020Future Science OA4 citations Open access
Semantic Scholar
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
G. Rinnerthaler, C. Singer, E. Petru, D. Egle +14 more
2022Wiener Klinische Wochenschrift3 citations Open access
Semantic Scholar
Abstract P1-21-08: Brain metastases (BM) from breast cancer: Real-word data from the Austrian AGMT_MBC-registry
S. Gampenrieder, G. Rinnerthaler, C. Tinchon, A. Petzer +13 more
2022Cancer Research3 citations
Semantic Scholar
Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial
D. Egle, D. Hlauschek, S. Gampenrieder, G. Rinnerthaler +17 more
2026npj Breast Cancer2 citations Open access
Semantic Scholar
123O Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABCSG-52/ATHENE)
G. Rinnerthaler, D. Egle, R. Bartsch, C. Schmitt +16 more
2023ESMO Open2 citations Open access
Semantic Scholar
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
R. Bartsch, S. Gampenrieder, G. Rinnerthaler, E. Petru +6 more
2022Wiener Klinische Wochenschrift2 citations Open access
Semantic Scholar
Top 3 abstracts concerning hormone-receptor-positive early breast cancer
S. Gampenrieder, G. Rinnerthaler, R. Greil
2021memo - Magazine of European Medical Oncology2 citations Open access
Semantic Scholar
Transferring MINDACT to Daily Routine: Implementation of the 70-Gene Signature in Luminal Early Breast Cancer – Results from a Prospective Registry of the Austrian Group Medical Tumor Therapy (AGMT)
T. Westphal, S. Gampenrieder, G. Rinnerthaler, M. Balić +9 more
2021Breast Care2 citations Open access
Semantic Scholar
Different types of electrostimulation target specific impaired sensory and motor functions in chemotherapy-induced peripheral neuropathy: a secondary analysis of a controlled trial
Florian Rieder, R. Sassmann, Y. Kienberger, V. Castagnaviz +7 more
2026Frontiers in Neurology1 citations
Semantic Scholar
Austrian treatment algorithms 2025: CDK 4/6 inhibitors in the adjuvant therapy of HR+/HER2− early breast cancer
R. Bartsch, C. Dormann, D. Egle, S. Gampenrieder +4 more
2026Wiener Klinische Wochenschrift1 citations Open access
Semantic Scholar
Post San Antonio 2024 update: chemotherapy, immunotherapy and management of side effects
S. Gampenrieder, V. Castagnaviz
2025memo - Magazine of European Medical Oncology1 citations Open access
Semantic Scholar
A comparison of breast cancer incidence and cancer stages before and after the introduction of the Austrian national breast cancer screening program in the federal state of Salzburg
S. Gampenrieder, Marc Vaisband, G. Rinnerthaler, Lukas Weiss +3 more
2025Wiener Klinische Wochenschrift1 citations Open access
Semantic Scholar
356P Real-world (RW) outcomes with first-line (1L) ribociclib (RIB)+endocrine therapy (ET) in patients (pts) with HR+, HER2– metastatic breast cancer (MBC): Final analysis of the phase IV REACH AUT study
C. Singer, D. Egle, S. Gampenrieder, E. Petrů +16 more
2025ESMO Open1 citations Open access
Semantic Scholar
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials
K. Wimmer, D. Hlauschek, M. Balić, G. Pfeiler +14 more
2025Breast1 citations Open access
Semantic Scholar
Antibody–drug conjugates (ADC special)—part 1
S. Gampenrieder
2024memo - Magazine of European Medical Oncology1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Rinnerthaler×40
Invite
G. Rinnerthaler — researcher profile on SciRah
R. Greil×26
Invite
R. Greil — researcher profile on SciRah
M. Balić×18
Invite
M. Balić — researcher profile on SciRah
D. Egle×17
Invite
D. Egle — researcher profile on SciRah

×8

Invite

A. Petzer — researcher profile on SciRah

Invite

R. Bartsch — researcher profile on SciRah

Invite

C. Suppan — researcher profile on SciRah

Invite

T. Westphal — researcher profile on SciRah

Invite

G. Pfeiler — researcher profile on SciRah

Invite

C. Fesl — researcher profile on SciRah

Invite

C. Singer — researcher profile on SciRah

Invite

C. Singer — researcher profile on SciRah